Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
$1.99
-$0.10(-5.75%)
At close: 4:00 PM EST
$1.99
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.83 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)757.02K
Market Cap
$123.91M
Enterprise Value$149.03M
Total Cash (Recent Filing)$77.73M
Total Debt (Recent Filing)$19.07M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding62,264,214
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.76
Price to Sales (P/S)5.65
P/FCF Ratio-1.57
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue52.85
Enterprise Value/Gross Profit52.85
Enterprise Value/Ebitda-1.83
Forecast
1Y Price Target
$6.90Price Target Upside246.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe confirmed ORR for 2/3L monotherapy in PD-(L)1 and platinum chemo experienced patients was 60%, exceeding the anticipated ORR in the mid-30s%.
CollaborationsPyxis Oncology has a clinical trial collaboration agreement with Merck for the combination with Keytruda.
Investor RecommendationsAnalyst recommends risk-tolerant long-term investors establishing positions in PYXS ahead of the data release, viewing it as a high-impact catalyst.
Bears Say
Cash ReservesThe company has approximately one year of cash left based on the current annualized cash burn.
Financial ChallengesDepleting cash reserves and ambiguous clinical data complicate analyst's recommendation.
Patient EnrollmentThe small sample size and the gradual pace of enrollment could cause concerns among investors.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $123.91M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Mar 25, 2026 which is in 68 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Nov 03, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.016.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.33.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 62,264,214 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 7.022%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.90 (246.73% Upside)
$6.90 (246.73% Upside)
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 53.7%
Last 30 Days ▲ 53.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
-45.93%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.90
▲(246.73% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
10.26%
Insiders
3.80% Mutual Funds
30.36% Other Institutional Investors
51.52% Public Companies and Individual Investors